
Allocetra™-OTS, a cellular immunomodulatory therapy, exhibited safety and efficacy in treating severe/critical COVID-19 with acute respiratory distress syndrome (ARDS). No serious adverse events were reported among patients who experienced rapid ARDS resolution and reduced inflammation markers. Promising results suggest Allocetra™-OTS's potential for managing COVID-19 hyper-inflammation.
Like
Save
Share